A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).
RACE Act is significantly changing clinical development. Are you ready?
Our team is here to help you navigate this historic transition in our industry.
Early Phase Innovative Pediatric Oncology Program Achieves Successful First Multiple Solid Tumors Study
PRA partnered with the sponsor’s new pediatric oncology department on an innovative pediatric oncology program. The program provided early evaluation…
Ask the Experts: Understanding Juvenile Idiopathic Arthritis
In light of JIA Awareness Month, its treatments, its stigma, and more, we spoke with Dr. Johnny Peppers, Executive Director of Drug Development for…